Articles and Blogs

After a slow start to the year, the Food and Drug Administration’s (“FDA”) Office of Prescription Drug Promotion (“OPDP”) now has a total of five enforcement letters for 2023 (four Untitled Letters and one Warning Letter) with potentially the last two letters of 2023 issued on Halloween. Our summary of the first three letters can…Read More

Hospitalogy published a roundup of recent earnings reports for a number of health systems. Several large, nonprofit health systems experienced losses in the recently ended quarter, while CVS Health and other for-profit providers reported profits and earnings growth. A recent Bisnow article indicated that, despite showing more resilience than the general office sector, the medical…Read More

The Sixth Circuit Court of Appeals (“the Court”) recently affirmed the dismissal of a nursing student intern’s lawsuit alleging disability discrimination and failure to accommodate claims. The Court opined that the plaintiff in this action failed to establish an intentional discrimination claim against Hurley Medical Center (“Hurley”) and that Hurley did not fail to provide…Read More

The Centers for Medicare & Medicaid Services (“CMS”) finalized significant updates to the Hospital Price Transparency regulation for the first time since the rule took effect on January 1, 2021. Many of the changes included in the CY 2024 Medicare OPPS and ASC Final Rule will affect all hospitals and necessitate updates, modifications and in some…Read More

Mayo Clinic unveiled a $5B plan to redesign its Rochester, Minnesota campus. The plan includes creating “health neighborhoods” within the campus that will focus on certain patient needs. CommonSpirit Health has closed on a $5M impact investment to support an affordable housing community in San Francisco called Freedom West Homes. Becker’s published a summary of…Read More

On September 29, 2023, the Food and Drug Administration (“FDA”) announced the issuance of a Notice of Proposed Rulemaking (the “Proposed Rule”) to expand the FDA’s regulatory scope over in vitro diagnostics products (“IVDs”) to specifically address Laboratory Developed Tests (“LDTs”). Traditionally, the FDA exercised enforcement discretion over LDTs, meaning that the FDA has not…Read More

On November 2, 2023, the Centers for Medicare & Medicaid Services (“CMS”) issued the 2024 Medicare Physician Fee Schedule Final Rule (“Final Rule”) for calendar year (“CY”) 2024. Among other changes, the Final Rule refines and builds on changes finalized in the CY 2023 Physician Fee Schedule Final Rule to the Medicare Shared Savings Program…Read More